|Bid||3.4500 x 800|
|Ask||3.6000 x 800|
|Day's Range||3.4700 - 3.6000|
|52 Week Range||1.0400 - 14.6000|
|Beta (3Y Monthly)||2.68|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 1) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...
Achieve Life Sciences, Inc. (ACHV) released its financial results for 2018 and filed the companion 10-K for the year ending December 31, 2018 on March 14, 2019. An investor conference call was held following the release to discuss recent achievements and financial results. Since our initiation, the company initiated a maximum tolerated dose (MTD) trial to examine the feasibility of a higher dose as they move into a Phase III trial.
Achieve Life Sciences, Inc. (ACHV) is developing cytisinicline, historically known as cytisine, for nicotine addiction. Achieve has licensed cytisinicline for development and commercialization in the United States and most other geographies around the world including parts of Europe, the Middle East, Africa and Asia. The drug formulation has been used by over 20 million smokers in Central and Eastern Europe for smoking cessation and also in over 2,000 subjects in previously conducted investigator-led Phase 3 clinical trials.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! The big shareholder groups in Achieve Life Sciences, Inc. (NASDAQ:ACHV)Read More...
Shares of Achieve Life Sciences Inc. rocketed 73% to pace all premarket gainers in active trade Friday, after the company reported upbeat results from a trial of its smoking-cessation drug. Trading volume reached 1.8 million shares ahead of the open, compared with the full-day average of about 151,000 shares. The company said it evaluated repeat doses of cytisinicline in 26 healthy volunteer smokers, who smoked an average 17.2 cigarettes a day. By the 26th day of treatment, there was an averag80% reduction in cigarettes smoked, 82% reduction in expired carbon monoxide and 46% had stopped smoking. Cytisinicline was well tolerated, with only "transient, mild-to-moderate headache" as the most common adverse event. "Given the short 25-day treatment period, the abstinence rates observed are impressive, particularly since subjects were not required to commit to quitting and received minimal behavioral support during the study," said Chief Medical Officer Cindy Jacobs. The stock has tumbled 87% over the past 12 months through Thursday, while the S&P 500 has gained 2.6%.
Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals
After an impressive 48.8% gain last week by Achieve Life Sciences (NASDAQ:ACHV) stock, ACHV stock has given up nearly all of its gains this week. ACHV stock price jumped on Sept. 27 after the company reported the results of a clinical study, but the shares went on to lose practically all of their gains by Oct. 1. ACHV stated that a new formulation of its smoking cessation aid – cytisine – showed similar bioavailability when the subjects were fed and when they fasted.
Achieve Life Sciences Inc (NASDAQ: ACHV) shares are skyrocketing as the clinical-stage biotech moves one step closer to filing a New Drug Application for its smoking cessation pipeline candidate cytisine. The company said it will conduct a Phase 2b optimization trial in about 250 smokers in the U.S., with various dosing schedules to determine efficacy, safety and compliance profiles.
Achieve Life Sciences Inc (NASDAQ: ACHV ) shares were posting double-digit gains Tuesday on roughly 83 times the stock's average volume. The stock was up 31 percent at the time of publication at $4.97. ...
In this article, I will take a quick look at Achieve Life Sciences Inc’s (NASDAQ:ACHV) recent ownership structure – an unconventional investing subject, but an important one. Ownership structure ofRead More...